Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $84.15 | Total: $420.75 |
| 1 | 10 | $71.28 | Total: $712.80 |
| 1 | 25 | $60.39 | Total: $1,509.75 |
| 1 | 50 | $51.48 | Total: $2,574.00 |
| 1 | 100 | $44.55 | Total: $4,455.00 |
Overview
TC-I 2014 shows antiallodynic properties in pain models. TC-I 2014 is a potent and orally active Benzimidazole-containing transient receptor potential melastatin 8 antagonist (IC50: 0.8 nM, 3.0 nM, and 4.4 nM for canine, human and rat channels respectively).
Chemical Properties
| Molecular Formula | C23H19F6N3O |
| Molecular Weight | 467.41 |
| CAS Numbers | 1221349-53-6 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | FC(F)(F)c1ccccc1-c1cc(c2[nH]c(nc2c1)C1=NOC2(C1)CCCCC2)C(F)(F)F |
Storage and Handling
0C Short Term, -20C Long Term
References
Parks DJ, et Design and optimization of benzimidazole-containing transient receptor potential melastatin 8 [TRPM8] antagonists. J Med Chem. 2011 Jan 13;54[1] 233-47.